110 related articles for article (PubMed ID: 31191537)
21. Author Correction: Suppression of IRF9 Promotes Osteoclast Differentiation by Decreased Ferroptosis via STAT3 Activation.
Lan C; Zhou X; Shen X; Lin Y; Chen X; Lin J; Zhang Y; Zheng L; Yan S
Inflammation; 2024 Mar; ():. PubMed ID: 38488993
[No Abstract] [Full Text] [Related]
22. The p52 isoform of SHC1 is a key driver of breast cancer initiation.
Wright KD; Miller BS; El-Meanawy S; Tsaih SW; Banerjee A; Geurts AM; Sheinin Y; Sun Y; Kalyanaraman B; Rui H; Flister MJ; Sorokin A
Breast Cancer Res; 2019 Jun; 21(1):74. PubMed ID: 31202267
[TBL] [Abstract][Full Text] [Related]
23. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract][Full Text] [Related]
24. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs.
Polak KL; Tamagno I; Parameswaran N; Smigiel J; Chan ER; Yuan X; Rios B; Jackson MW
Mol Cancer Res; 2023 Sep; 21(9):975-990. PubMed ID: 37310811
[TBL] [Abstract][Full Text] [Related]
25. From Stem to Sternum: The Role of Shp2 in the Skeleton.
Jensen NR; Kelly RR; Kelly KD; Khoo SK; Sidles SJ; LaRue AC
Calcif Tissue Int; 2023 Apr; 112(4):403-421. PubMed ID: 36422682
[TBL] [Abstract][Full Text] [Related]
26. Topography-mediated immunomodulation in osseointegration; Ally or Enemy.
Shirazi S; Ravindran S; Cooper LF
Biomaterials; 2022 Dec; 291():121903. PubMed ID: 36410109
[TBL] [Abstract][Full Text] [Related]
27. Oncostatin M receptor regulates osteoblast differentiation via extracellular signal-regulated kinase/autophagy signaling.
Zhou J; Yang J; Dong Y; Shi Y; Zhu E; Yuan H; Li X; Wang B
Stem Cell Res Ther; 2022 Jun; 13(1):278. PubMed ID: 35765036
[TBL] [Abstract][Full Text] [Related]
28. Oncostatin M Induces Lipolysis and Suppresses Insulin Response in 3T3-L1 Adipocytes.
Bailey JL; Hang H; Boudreau A; Elks CM
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563078
[TBL] [Abstract][Full Text] [Related]
29. Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) accelerates osteoclast formation by regulating signal transducer and activator of transcription 3 (STAT3) signalling.
Xue Y; Zhao C; Liu T
Bioengineered; 2022 Feb; 13(2):2285-2295. PubMed ID: 35034537
[TBL] [Abstract][Full Text] [Related]
30. WNT16 is Robustly Increased by Oncostatin M in Mouse Calvarial Osteoblasts and Acts as a Negative Feedback Regulator of Osteoclast Formation Induced by Oncostatin M.
Henning P; Movérare-Skrtic S; Westerlund A; Chaves de Souza PP; Floriano-Marcelino T; Nilsson KH; El Shahawy M; Ohlsson C; Lerner UH
J Inflamm Res; 2021; 14():4723-4741. PubMed ID: 34566421
[TBL] [Abstract][Full Text] [Related]
31. Mapping the immune microenvironment for mandibular alveolar bone homeostasis at single-cell resolution.
Lin W; Li Q; Zhang D; Zhang X; Qi X; Wang Q; Chen Y; Liu C; Li H; Zhang S; Wang Y; Shao B; Zhang L; Yuan Q
Bone Res; 2021 Mar; 9(1):17. PubMed ID: 33723232
[TBL] [Abstract][Full Text] [Related]
32. Association of Genetic Polymorphisms in
Fan Y; Gu X; Pan H; Dai Z; Zou C; Gao Z; Zhang H
J Oncol; 2020; 2020():4103264. PubMed ID: 32655638
[TBL] [Abstract][Full Text] [Related]
33. Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor.
Persson E; Souza PPC; Floriano-Marcelino T; Conaway HH; Henning P; Lerner UH
Front Immunol; 2019; 10():1164. PubMed ID: 31191537
[No Abstract] [Full Text] [Related]
34. Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.
de Souza PPC; Henning P; Lerner UH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328707
[TBL] [Abstract][Full Text] [Related]
35. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
Palmqvist P; Persson E; Conaway HH; Lerner UH
J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
[TBL] [Abstract][Full Text] [Related]
36. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone.
Richards CD; Langdon C; Deschamps P; Pennica D; Shaughnessy SG
Cytokine; 2000 Jun; 12(6):613-21. PubMed ID: 10843736
[TBL] [Abstract][Full Text] [Related]
38. Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.
Sims NA; Lévesque JP
Curr Osteoporos Rep; 2024 Feb; 22(1):80-95. PubMed ID: 38198032
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
